Answers are grounded in this paper and cite their sources.
Proposed bills enhance patients' control in oncology trials, promoting data autonomy and participation.
The cancer patient, not the doctor, the nurse, the trial sponsor, the IRB, or the regulator, is the priority participant in any United States oncology clinical trial. Advanced AI and advanced robotics now offer the patient direct control over discovery, enrollment, scheduling, robot selection, procedural modification, real-time data feedback, and self-custody of health data. Proposed bills HR 9501 through HR 9507 supply the legal infrastructure for that control.
No takes yet. Share an insight, caveat, or question.
Kevin Kawchak (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: